Smad transcription factors mediate the growth inhibitory effect of transforming growth factor-b (TGF-b) in many cell types. Mutational inactivation of Smads has been correlated with loss of responsiveness to TGF-b-mediated signal transduction. In this study, we compare the contribution of individual Smads to TGF-b-induced growth inhibition and endogenous gene expression in isogenic cellular backgrounds. Smad2, Smad3 and Smad4 expression were selectively inhibited in differentiationcompetent cells by using improved antisense molecules. We found that TGF-b mediates its inhibitory effect on HaCaT keratinocyte cell growth predominantly through Smad3. Inhibition of Smad3 expression was sufficient to interfere with TGF-b-induced cell cycle arrest and to induce or suppress endogenous cell cycle regulators. Inhibition of Smad4 expression exhibited a partial effect, whereas inhibition of Smad2 expression had no effect. By gene expression profiling, we identified TGF-b-dependent genes that are differentially regulated by Smad2 and Smad3 under regular growth conditions on a genome-wide scale. We show that Smad2, Smad3 and Smad4 contribute to the regulation of TGF-b responses to varying extents, and demonstrate, in addition, that these Smads exhibit distinct roles in different cell types.
Introduction
Tissue growth and homeostasis are controlled by a balanced crosstalk between intracellular signals that mediate cell growth and survival, as well as those that mediate differentiation and apoptosis. Understanding the network of signal transduction pathways that regulate these events in a controlled, specific and timely fashion will be crucial to develop new strategies for therapeutic intervention of diseases such as cancer. Signal transduction induced by transforming growth factor-b (TGF-b) and related cytokines regulates a variety of cellular responses such as proliferation, migration, apoptosis, extracellular matrix formation, differentiation or morphogenesis, depending on the cellular context (for reviews covering various aspects, see Derynck and Feng, 1997; Piek et al., 1999; Roberts, 1999; Massague, 2000; Wrana, 2000; Wrana and Attisano, 2000) . Binding of TGF-b to its cognate receptor activates the receptor kinase, which then phosphorylates and activates members of the Smad family of signaling molecules. The receptor-regulated Smads (R-Smads), Smad2 and Smad3, are then able to translocate to the nucleus due to their association with Smad4, which functions as common-mediator Smad (Co-Smad) for the regulation of TGF-b-dependent gene expression (Hill, 1999; Zhang and Derynck, 1999; Attisano and Wrana, 2000; Massague and Wotton, 2000; Moustakas et al., 2001) . The heteromeric Smad complex recruits various cofactors to regulate transcription of specific target genes. Although additional signaling pathways might contribute to TGF-b-induced responses, Smads are the only direct effectors known to act as transcription factors and therefore represent the most direct mediators for the transmission of signals from the cell surface into the nucleus (Hill, 1999; Massague, 2000; Wrana, 2000; Wakefield and Roberts, 2002) .
TGF-b inhibits cell growth of normal epithelial cells by inducing an arrest in the G1 phase of the cell cycle. The cytostatic function of TGF-b is believed to contribute to tissue homeostasis and protection against oncogenic transformation (Hill, 1999; Massague, 2000; Wakefield and Roberts, 2002) . Loss of the antiproliferative responsiveness to TGF-b is a characteristic of many tumor cells (Hanahan and Weinberg, 2000) . Loss of responsiveness to TGF-b-mediated growth inhibition can be caused by deregulation of various components of the TGF-b signaling cascade including the Smad proteins. For example, inactivating mutations in Smads are frequently associated with tumors in certain human tissues (Massague, 2000; Wakefield and Roberts, 2002) .
To investigate the relative contribution of individual Smad proteins to TGF-b signaling, the effects of targeted disruption of Smad genes have been analysed in mice (Weinstein et al., 2000) . Since Smad2 and Smad4 knockout mice die at an early stage during embryogenesis, it was not possible to investigate the effects of a complete loss of function of these Smad molecules in differentiated tissues (Nomura and Li, 1998; Sirard et al., 1998; Waldrip et al., 1998; Weinstein et al., 1998; Yang et al., 1999) . In alternative approaches, the effects of transient overexpression of Smads on reporters with artifical promoters were determined. However, in certain cases the regulation of endogenous genes might have substantially different requirements than the expression of a reporter cDNA from a transiently transfected vector as demonstrated in a study using Smad4 knockout fibroblasts (Sirard et al., 2000) . Overexpression of transcription factors such as Smads may not always accurately reconstitute the functional state of the endogenous molecules with respect to oligomerization or complex formation (see, Gill and Ptashne, 1988; Jayaraman and Massague, 2000) .
Up to now, inhibition of Smad2, Smad3 and Smad4 function has never been compared side-by-side in an isogenic background to identify the role of the individual molecules in mediating the growth inhibitory effect of TGF-b. The need for an unbiased approach in such a comparative study is reflected by the observation that Smad2-and Smad3-deficient mouse embryo fibroblasts exhibit disturbances in basal expression levels of target genes as well as in their basal proliferation rates compared to wild-type cells (Piek et al., 2001) . In this report, we have therefore used improved antisense molecules, the so-called GeneBlocs (GBs) (Sternberger et al., 2002) , to inhibit selectively expression of Smad2, Smad3 and Smad4 in parallel in two differentiationcompetent human cell lines, HaCaT keratinocytes and MCF-10A breast epithelial cells. Both are immortalized, nontransformed human cell lines that respond to TGF-b (Boukamp et al., 1988; Soule et al., 1990; Game et al., 1992; Basolo et al., 1994) and retain the capacity for further differentiation (Blaschke et al., 1994; Schoop et al., 1999) . By 'induced inhibition' of gene function using GBs, we mimic loss of Smad function to study the resulting molecular consequences that might contribute to tumorigenesis. This transient approach does not allow for compensatory mechanisms to take action in cells, and enables us to analyse the effects on TGF-b signaling by monitoring endogenous responses. We demonstrate that individual Smads make distinct contributions to various TGF-b responses: Smad3 appears to be the key mediator of TGF-b signaling in HaCaT keratinocytes, while Smad2, Smad3 and Smad4 appear to be rather equally required in MCF-10A breast epithelial cells.
Results

GB treatment of
HaCaT keratinocytes leads to efficient downregulation of Smad2, Smad3 or Smad4 mRNA and protein levels
To identify GB antisense molecules that successfully interfere with the expression of Smad2, Smad3 and Smad4, we screened a panel of eight GBs per target for inhibition of expression of the respective mRNA in HaCaT cells. Under the conditions used the transfection efficiency was optimized to be at least 95% (Sternberger et al., 2002) . Three different GB molecules (A, B, C) were selected for each target and further tested for efficacy in a dose-response experiment. Control samples were treated with a GB control (GBC) molecule, which represents a mix of all possible GB sequences with a synthesis complexity of 4 23 (see Materials and methods for details). All the selected Smad-directed antisense molecules caused a significant downregulation of Smad2, Smad3 or Smad4 mRNA as determined by real-time RT-PCR (Taqman) analysis. The observed reductions in mRNA levels were up to 95% depending on the GB molecule and the concentration of GB that was used (Figure 1a) . Overall, the most robust knockdown in gene expression was observed at 30 nM GB concentration, which was used for subsequent experiments.
We next wanted to test whether the reduction in mRNA expression induced by GB treatment also resulted in a robust reduction of Smad protein levels ( Figure 1b ). HaCaT keratinocytes were continuously transfected with three different GBs for each Smad. Every GB was controlled by a corresponding four nucleotide mismatch control antisense molecule ('mm'). Protein expression of Smad2, Smad3 or Smad4 was analysed by Western blotting of cell extracts after 48 h. The three lead GBs selected for each Smad molecule also efficiently inhibited Smad protein expression (Figure 1b) . None of the GB or mismatch controls interfered with the expression of p110, the catalytic subunit of phosphatidylinositol (PI) 3-kinase, which served as a loading control on the same Western blot membrane. Under the conditions used, the cells continued to proliferate under persistent GB treatment (see below and Sternberger et al., 2002) . Maximal downregulation of Smad protein expression could be observed between 36 and 48 h after GB addition and persisted during continuous treatment (up to 5 days were determined; data not shown).
To analyse the specificity of GB-induced protein knockdown, GBs specific for Smad2, Smad3 or Smad4 were tested for their effect on the expression of other Smad family members by Western blotting. The close homology of Smad2 and Smad3 is reflected by the fact that both proteins can be detected by one polyclonal antibody (Figure 1c ). The Smad2 GB reduced Smad2 protein expression, whereas the protein levels of Smad3 and Smad4 were not affected. Similarly, Smad3-or Smad4-directed GB molecules specifically inhibited expression of the respective Smad proteins. All other Smad GBs used in this study exhibited similar specificity (Figures 2 and 6 and data not shown).
Inhibition of Smad2, Smad3, or Smad4 expression differentially affects TGF-b-downstream effectors
There is increasing evidence that Smads might also regulate protein turnover and stability in addition to their function as transcriptional regulators (Moustakas et al., 2001; Roberts and Derynck, 2001 ; Attisano and Figure 1 GBs efficiently downregulate Smad2, Smad3 and Smad4 expression in HaCaT keratinocytes. (a) GB-induced downregulation of Smad mRNA. Subconfluent HaCaT cells were transfected in 96-well plate (1500 cells/well) with the indicated amounts of GBs specific for Smad2 (GB 2A, 2B, 2C), Smad3 (GB 3A, 3B, 3C), Smad4 (GB 4A, 4B, 4C), or a randomized GBC or were left untreated (ut). After ca. 24 h RNA was prepared and subjected to real-time PCR (Taqman) analysis. Smad mRNA levels are shown relative to the mRNA levels of b-actin, which served as internal reference. Each bar represents triplicate transfections7s.d. (b) GBmediated inhibition of Smad protein expression. Subconfluent HaCaT cells (400 000 cells per 10-cm plate) were transfected with 30 nM of the GBs described in (a). Each GB is controlled by its corresponding four nucleotide mm. After 48 h of incubation, cell extracts were separated by 8% SDS-PAGE and analysed by Western blotting using Smad2; Smad3-or Smad4-specific antibodies as indicated in the lower panel for each Smad. The catalytic subunit of PI 3-kinase, p110, served as loading control and was detected by an anti-p110 antibody (upper panels). The positions of p110 and each Smad are indicated on the right. (c) GB-mediated inhibition of Smad protein expression is specific. HaCaT cells were transfected in 10-cm plates with 30 nM of GB or mm specific for Smad2, Smad3, and Smad4 as indicated. Cell extracts were analysed in parallel for expression of each Smad using an antibody that detects both, Smad2 and Smad3 (lower panel), and a Smad4-specific antibody (medium panel), p110 served as loading control (upper panel) Wrana, 2002) . Therefore, we analysed TGF-b-induced changes on protein rather than RNA level whenever possible.
Our approach of 'induced inhibition of gene expression' to study gene function has the potential caveat that residual amounts of protein may be sufficient to exert almost normal function. In this case, a possible change in phenotype would remain obscured. To test for functionality of the Smad inhibition achieved by our approach, we looked at several TGF-b response genes including type 2 transglutaminase (TGase-2) (George et al., 1990) , heme oxygenase 1 (HO-1) (Hill-Kapturczak et al., 2000) and inhibitor of DNA-binding 1 (ID-1) (Ling et al., 2002) . HaCaT cells were transfected with the indicated GBs or mismatch controls for 24 h and subsequently incubated with or without TGF-b overnight. Equal amounts of cell extracts were analysed by Western blotting; p110 served as loading control ( Figure 2 ). As expected, addition of TGF-b strongly induced the expression of TGase-2 and HO-1, whereas Figure 2c , lanes 1-4). The expression of one of the TGF-b response genes, HO-1, was dependent on the presence of all three Smads: All GBs tested (three each for Smad2 and Smad3, two for Smad4) interfered with TGF-b-induced HO-1 expression (Figure 2a , b, lanes 7-9; lanes 5-6). The corresponding mismatch control molecules had no effect. By contrast, TGase-2 expression was mostly dependent on Smad3 and to a lesser extent also on Smad4. TGF-b-induced repression of ID-1 expression, however, was selectively reversed by Smad3 GB treatment demonstrating a distinct role of Smad3 in TGF-b-induced ID-1 suppression. From this experiment, we have drawn the following conclusions: First, GB-mediated inhibition of all three Smads is indeed functional, since treatment with GBs specific for either Smad2, Smad3 or Smad4 interfered with TGF-b induction of HO-1. This implies that we can reach valid conclusions about the role of individual Smad proteins for TGF-b-mediated cellular responses by using this approach. Second, there are differential requirements for Smad2, Smad3 and Smad4 for the regulation of TGF-b-mediated gene expression.
Inhibition of Smad3 protein expression allows HaCaT keratinocytes to escape from TGF-b-induced cell cycle arrest
After ensuring efficacy and specificity of GB-mediated inhibition of Smad expression, we next investigated the role of Smad2, Smad3 and Smad4 on TGF-b-induced cell cycle arrest. After release into the cell cycle by serum stimulation in the presence of TGF-b, the majority of HaCaT cells remained in G 0 /G 1 similar to control cells that were kept under serum deprivation ( Figure 3a ). Cells that were released in the absence of TGF-b re-enter the cell cycle as represented by increased fractions of cells in S and G 2 /M phases. To test whether inhibition of Smad2, Smad3 or Smad4 expression can modulate the inhibitory effect of TGF-b on HaCaT cell cycle entry, GB or mismatch molecule (mm)-treated cells were first synchronized by low serum treatment overnight. Next, the cells were released into the cell cycle by the addition of serum either in the presence or absence of TGF-b for approximately 18 h. The growth inhibitory effect of TGF-b is typically measured between 16 and 24 h of stimulation (Ashcroft et al., 1999; Datto et al., 1999; Sirard et al., 2000; Chen et al., 2001; Piek et al., 2001) . After fixing and staining, the DNA content of the cells was determined by flow cytometry (Figure 3b ). Successful inhibition of Smad expression was determined by Western blotting analysis of parallel samples (see Figure 4) . At least two different GB/mismatch ('GB/mm') combinations were tested per Smad target, and a representative experiment is shown for Smad2, Smad3 and Smad4 (Figure 3b ). In each case, mismatch antisense-treated cells behaved like the untransfected cells shown in Figure 3a : After serum stimulation the cells entered the S and G2/M phases of the cell cycle. However, treatment with TGF-b resulted in a large fraction that remained arrested in G 0 /G 1 . GB-mediated inhibition of Smad2 had no effect on this TGF-b response ( Figure 3b , upper panel). However, GB-mediated inhibition of Smad3 abrogated the TGF-b-induced cell cycle arrest since the cells exhibited a similar cell cycle distribution as samples without TGF-b (middle panel). Cells treated with Smad4 GB were partially, but reproducibly able to escape the arrest (lower panel). A bar diagram summarizes the results obtained with two different GB/mm combinations tested for each Smad target (Figure 3c ), indicating that the data are indeed consistent. Inhibition of Smad3 expression has the strongest effect, inhibition of Smad4 has a partial effect, and inhibition of Smad2 has no detectable effect on TGF-b-mediated growth inhibition. From these data, we conclude that Smad3 is the predominant mediator of TGF-b-induced cell cycle arrest in HaCaT cells.
Smad3 function is required for TGF-b-mediated changes on cell cycle regulators in HaCaT cells
To understand the molecular basis for the observation that TGF-b seems to mediate its inhibitory effect on HaCaT cell growth predominantly via Smad3, we analysed the expression or activation status of several endogenous downstream effectors of TGF-b known to be crucial regulators of cell cycle progression. The samples for this Western blot analysis were prepared in parallel to the samples processed for the cell cycle analysis shown above. Previous studies have focused on identifying the immediate-early and direct effectors of TGF-b. We intended here to establish how TGF-b regulates the inhibition of cell growth and the Smad dependence of this effect. Therefore, the Western blot analysis on TGF-b-dependent regulators of cell cycle progression was performed using samples that had been treated for 16 h, a time point at which growth inhibition starts to become apparent (Ashcroft et al., 1999; Datto et al., 1999; Sirard et al., 2000; Chen et al., 2001; Piek et al., 2001) .
As expected, TGF-b treatment strongly increased the expression of the cell cycle inhibitors p15
Ink4b and p21 Cip1/Waf , which correlated with activation of the retinoblastoma tumor suppressor molecule, Rb, as detected by its dephosphorylation (Figure 4a , b, lanes 1-6; Figure 4c, lanes 1-4) . Similarly, TGF-b treatment is known to inhibit expression of the c-Myc proto-oncogene (Pietenpol et al., 1990) . The level of p110, which served as loading control, was changed neither by TGF-b nor GB treatment (Figure 4a-c) . All three Smad2 GBs induced a substantial reduction in Smad2 protein levels (Figure 4a , lanes 7-9); however, this did not significantly affect any of the TGF-b-regulated responses. In some cases, Smad2 inhibition appeared to interfere with p15 induction (lanes 7 and 9), but this effect remained partial and was not consistently detected in independent experiments. Suppression of Smad3 also showed only a partial inhibitory effect on p15 induction; by contrast, it strongly interfered with TGFb-induced p21
Cip1 expression with each of the three GBs These data suggest that Smad3 is the predominant mediator of TGF-b-induced growth inhibition in HaCaT keratinocytes by modulating expression of cMyc and p21
Cip1
, and the phosphorylation status of Rb. In addition, ID-1 expression, which is indicative of proliferating cells, was selectively restored by Smad3 inhibition (Figure 2 ). Smad4 also contributes to the TGF-b-induced effect, albeit to a lesser extent than Smad3. Its inhibition resulted in a partial release from cell cycle arrest, which correlated with the partial effects on TGF-b-mediated gene expression and Rb dephosphorylation. Smad2 function was not substantially required for any of the immediate events that have been linked to the growth inhibitory effects of TGF-b, although it was required for TGF-b-induced HO-1 expression (see Figure 2a ).
Smad-dependent TGF-b responses are not affected by experimental conditions
The results obtained in the experiments described above were rather unexpected with respect to the role of individual Smad molecules. Therefore, we wanted to ensure that the conditions or reagents used to downregulate Smad expression did not affect the normal response of HaCaT cells to TGF-b treatment. Two sets of cells were transfected in parallel with two different Smad3 GBs or the corresponding mismatch controls. One set was released into the cell cycle in the absence, the second set in the presence of TGF-b. TGF-b-responsive gene expression was monitored by Western blotting ( Figure 5 ). Cells incubated without TGF-b exhibited comparable expression levels for the different TGF-b effectors, except for Smad3, which was substantially downregulated in the presence of each of the two Smad3 GBs. Mismatch GB-treated cells that were incubated in the presence of TGF-b showed the expected responses: the protein levels of TGase-2, plasminogen activator inhibitor 1 (PAI-1) and p21
Cip1 were induced, whereas phospho-Rb and ID-1 levels decreased. Inhibition of Smad3 interfered with these TGF-b responses in HaCaT cells (see also Extracts of HaCaT cells treated in parallel to the samples described in Figure 3 were analysed by Western blotting. (a) Inhibition of Smad2 expression. Cells were treated with mismatch (lanes 1-6) or Smad2 GBs (lanes 7-9) and released into the cell cycle in the absence (lanes 1-3) or presence (lanes 4-9) of TGF-b. Cell lysates were analysed by 8 and 16% SDS-PAGE followed by Western blotting. Equal loading and successful Smad2 knockdown were confirmed using anti-p110 and anti-Smad2/Smad3 antibodies, respectively. Induction or suppression of TGF-b responses was tested by using antiphospho Rb (P*-Rb) antibody, anti-c-Myc antibody, anti-p21
Cip1 antibody and anti-p15 Ink4b antibody. The positions of the respective proteins are indicated on the right. (b) Inhibition of Smad3 expression. Cells were treated with the indicated mismatch (lanes 1-6) or Smad3 GBs (lanes 7-9) and released into the cell cycle in the absence (lanes 1-3) or presence (lanes 4-9) of TGF-b. Cell extracts were analysed as described in (a); inhibition of Smad3 expression was confirmed using anti-Smad2/Smad3 antibodies. (c) Inhibition of Smad4 expression. HaCaT cells were incubated with the indicated mismatch (lanes 1-4) or Smad4 GBs (lanes 5-6) and allowed to re-enter the cell cycle without (lanes 1-2) or with TGF-b (lanes 3-6), and were further analysed as described under (a); the successful reduction in Smad4 expression was confirmed using an anti-Smad4 antibody. A representative experiment is shown for each set of Smad mismatch and GB molecules Analysis of Smad2-or Smad3-dependent expression of TGF-b response genes in HaCaT keratinocytes using gene expression arrays
Owing to the intriguing difference observed for the function of two proteins as homologous as Smad2 and Smad3 in regulating TGF-b signaling in HaCaT cells, we next used gene expression profiling to investigate the relative contribution of Smad2 or Smad3 for TGF-bregulated transcription. We were especially interested in analysing the differences in gene expression patterns that correlate with the escape from TGF-b-induced cell cycle arrest after Smad3 inhibition compared to the continued arrest after Smad2 inhibition. Therefore, distinct from previous studies the cells were maintained under optimal growth conditions (culture medium þ 10% fetal calf serum (FCS)) when treated with TGF-b. We transfected duplicate samples of HaCaTs with GBs specific for Smad2 (GB 2A), Smad3 (GB 3A) or with mismatch oligonucleotides (mm 3A), and then treated them with or without TGF-b for 6 h as described above. At this time point, we can detect TGF-b-specific changes in gene expression above the serum background. This time point also marks the onset of changes in protein levels of TGF-b effectors such as c-Myc (not shown) that regulate transcriptional activation/repression through which the growth inhibitory response may be controlled several hours later. One set of cells was subjected to RNA extraction and gene expression analysis using DNA microarrays and the second set served as control for Western blot analysis to verify the functional knockdown of Smad protein expression as determined above (not shown).
The DNA array analysis confirmed a substantial reduction in the amount of either Smad2 or Smad3 mRNA after treatment with the respective GBs (Table 1 , upper section). The knockdown achieved was specific for each Smad target RNA species by this method of analysis as well, since Smad2 or Smad3 GBs did not affect mRNAs encoding the other Smad family members. Table 1 (lower section) shows a panel of mRNAs that are up-or downregulated after 6 h TGF-b treatment in the presence of serum by 2.5-fold or more (see Materials and methods for the complete selection criteria). Four subsets of genes that were up-or downregulated after TGF-b treatment were identified: One subset appeared to be exclusively dependent on Smad2, a second subset on Smad3 and a third subset required both, Smad2 and Smad3 function. A fourth subset of genes did not appear to be dependent on either Smad2 or Smad3 for TGF-b-mediated regulation. The differential expression pattern through Smad-dependent regulation of several genes was verified by Taqman analysis as indicated (Table 1 , and data not shown). Owing to differences in approach and experimental conditions used, we observed only a partial overlap with the panel of typical TGF-b response genes: Since the TGF-b effects in our study needed to be detected above the serum growth factor background, a number of typical TGF-b effector genes stayed slightly below the 2.5-fold threshold that was applied for the list in Table 1 (for more details see the Discussion section). The complete set of primary data will be provided upon request. The array-based expression analysis confirmed that genes regulated by TGF-b in HaCaT cells depend to various degrees on the function of Smad2 and Smad3.
Smad2, Smad3 and Smad4 contribute equally to TGF-b signaling in MCF-10A cells
We were surprised to find such a predominant role of Smad3 for TGF-b responses in HaCaT cells. Therefore, we wanted to test the contribution of individual Smads in TGF-b-responsive cells that originate from a different tissue. MCF-10A breast epithelial cells are like HaCaT cells a nontransformed immortalized human line that responds to TGF-b (Basolo et al., 1994) . MCF-10A cells are p15
Ink4a deficient (Iavarone and Massague, 1997); also p21
Cip1 and phospho-Rb protein levels did not significantly change in response to TGF-b in this cell type (not shown). Therefore, we focused on analysing TGF-b reponses such as c-Myc, PAI-1 and TGase-2 expression after suppressing Smad function.
MCF-10A cells were treated with three different GBs for each Smad and incubated with or without TGF-b. Western blot analysis of cell extracts revealed that the same Smad GBs that were used for the experiments in (Figure 6a-c, lanes 7-9) . Samples treated with the corresponding mismatch GBs exhibited normal TGF-b responsiveness (lanes 1-6). Inhibition of Smad2 expression interfered with TGF-b-mediated induction of TGase-2 and PAI-1 (Figure 6a, lanes 7-9) . In addition, suppression of c-Myc by TGF-b was inhibited in the presence of all three GBs. Inhibition of either Smad3 or Smad4 expression was similarly effective in interfering with TGF-b signaling as Smad2 inhibition (Figure 6b, c, lanes 7-9) . Of three Smad4-specific GBs tested, GB 'C' was less potent in inhibiting Smad4 expression in MCF-10A compared to HaCaT cells (Figure 6c, lane 9) , which correlated with a reduced efficacy in its ability to counteract the TGF-b-induced effects and indicates a dose-dependent effect. In our hands, MCF-10A cells did not respond to the growth inhibitory effect of TGF-b, even though c-Myc levels were substantially downregulated by TGF-b, which was suggested to trigger growth inhibition in this cell type (Chen et al., 2001) . Therefore, it was impossible to investigate whether inhibition in Smad function would interfere with cell cycle arrest.
Our results demonstrate that Smad2, Smad3 and Smad4 can regulate different TGF-b-dependent responses to varying extents within one cell type. In addition, the relative contribution of individual Smads to TGF-b signaling appears to vary in different cell types.
Discussion
In this study, we compare for the first time the effect of inhibiting Smad2, Smad3 and Smad4 side-by-side in differentiation-competent cells and analyse the resulting effects on the endogenous TGF-b signal transduction machinery with respect to gene expression and growth inhibition. This was accomplished by selectively suppressing protein expression using GB antisense molecules against each individual Smad molecule. We thereby avoid problems typically associated with overexpression systems or knockout technologies (see Introduction). A potential caveat of our approach, however, is that we can only achieve a knockdown and never a complete loss of gene function. We therefore ensured functionality of the knockdown in order to reach valid conclusions about the role of individual Smad proteins for TGF-b-mediated cellular responses (Figures 2 and 6 and Table 1 ). We also used at least two, in many experiments even three independent GBs per target, each resulting in at least 90% reduction in protein expression compared to the corresponding mismatch controls.
We found that Smad2, Smad3 and Smad4 make different contributions to the regulation of endogenous TGF-b effectors in HaCaT cells, which indicates that different Smad complexes may be responsible for the regulation of different genes within one cell type. For example, HO-1 induction was dependent on the presence of all three Smads (Figure 2) , whereas other genes appeared to be selectively regulated by one Smad (Figures 2 and 4 and Table 1 ). Biochemical and crystallographic studies have shown that Smads can exist in a multitude of signaling complexes representing multiple oligomeric states that range from heterodimers to high molecular weight assemblies (Nakao et al., 1997; Jayaraman and Massague, 2000; Chacko et al., 2001; Correia et al., 2001; Wu et al., 2001; Qin et al., 2002) . Still, the exact stoichiometry of Smad complexes remains controversial (Inman and Hill, 2002; Moustakas and Heldin, 2002) . -9) , cell extracts were analysed by Western blotting as described in (a). Specific reduction of Smad3 expression was detected by using anti-Smad2/Smad3 and anti-Smad4 antibodies, respectively. (c) Inhibition of Smad4 expression in MCF-10A cells. Cells were treated with the indicated mismatch (lanes 1-6) or Smad4 GBs (lanes 7-9), or without GB (ut, lane 10). After incubation without (lanes 1-3 and 10) or with TGF-b (lanes 4-9) cells extracts were prepared and analysed as described in (a); the successful reduction in Smad4 expression was confirmed using an anti-Smad4 antibody. A representative experiment is shown for each set of Smad mismatch and GB molecules Smad2, Smad3 and Smad4 in TGF-b signalling A Kretschmer et al
To establish the contribution of individual Smads to TGF-b-mediated growth inhibition, we maintained the cells under optimal growth conditions in the presence of 10% FCS when TGF-b was added (Game et al., 1992; Cerezo et al., 2002) . Compared to previous studies using TGF-b in the absence of other growth factors, this means that TGF-b-specific effects needed to be detected above the serum growth factor background, which is complicated by the fact that certain genes are similarly regulated by growth factors and TGF-b (Werner et al., 2000) . This may account for the observation that several typical TGF-b effector genes stayed below the 2.5-fold threshold that was applied for the panel of differentially expressed genes shown in Table 1 , and could explain that only a partial overlap with DNA array analyses reported by others was detected (Chen et al., 2001; Zavadil et al., 2001) . Among the known downstream effector genes that remained slightly below the 2.5-fold cutoff change in expression after TGF-b treatment (according to the array software criteria) were c-myc, id-1, id-2, id-3, menin, p21
Ink4b , smad7, connective tissue growth factor, etc. (the complete data set will be provided upon request). Since we have analysed only one time point (6 h), we can also not rule out that some of the 'classical' TGF-b target genes are more significantly induced or inhibited at earlier or later time points under the conditions used here. In addition, the array analysis may underestimate the changes in expression as determined by real-time PCR (data not shown). The expression analysis presented in Table 1 is verified by the specific reduction in Smad2 or Smad3 mRNA levels detected after treatment with the respective GB (upper panel), and by the fact that typical TGF-b response genes such as HO-1, PAI-1, TGase-2, fibronectin-1 did pass the criteria for Table 1 .
The DNA array analysis presented in Table 1 reveals four different subsets of TGF-b responsive genes. The first set of genes is selectively regulated by Smad2, the second set by Smad3 and a third subset appears to be regulated by both, Smad2 and Smad3. Some Smad2-and Smad3-dependent genes exhibit a biased dependence on the function of one of the Smads (e.g. matrix metalloproteinase 9, Table 1), which is in agreement with the variability in oligomeric state and stoichiometry of the components in Smad signaling complexes. A fourth subset of genes was regulated by TGF-b in a Smad2-and 3-independent manner. A different class of genes not discussed here exhibited a strong dependence on the function of Smad2 or Smad3 despite the fact that their expression remained unchanged in response to TGF-b (not shown). This implicates Smad proteins in mediating responses other than TGF-b-regulated events.
Although Smad2 and Smad3 are highly homologous, they appear to exhibit distinct roles in TGF-b-mediated signal transduction in HaCaT cells (Figures 2-5 and Table 1 ). The fact that Smad2 cannot bind directly to DNA as compared to Smad3 is likely to contribute to the different functions of both proteins (Zhang and Derynck, 1999; Moustakas et al., 2001) .
We have shown that Smad3 appears to be the key mediator for TGF-b-induced cell cycle arrest in HaCaT keratinocytes, since inhibition of Smad3 expression was sufficient to release the cells into the cell cycle (Figure 3 ). This coincides with the observation that most TGF-b effectors involved in cell cycle regulation analysed here were Smad3-dependently regulated in HaCaTs (Figures 2 and 4) : Only the knockdown of Smad3 interfered with TGF-b-induced expression of p21
Cip1
, suppression of ID-1 and completely reversed Rb dephosphorylation. By contrast, Smad4 knockdown exhibited a partial effect on release from cell cycle arrest and on Rb dephosphorylation. The latter effect might be due to a partial reduction of p15
Ink4b levels in the absence of Smad4. Our finding on the role of Smad3 as principle mediator for TGF-b in HaCaT cells is in agreement with the reduced sensitivity of primary keratinocytes from Smad3-null mice to TGF-b-mediated growth inhibition (Ashcroft et al., 1999) . Loss of Smad3 protein expression in human tumor cells is not uncommon (Roehl and Klippel, unpublished; Xu et al., 2001 Xu et al., , 2003 Nicolas et al., 2003) , and recently it was even shown that resistance against TGF-b-induced growth arrest in epithelial cells is accompanied by selective downregulation of Smad3 expression (Nicolas et al., 2003) .
Smad3 also appears to be responsible for interfering with suppression of c-Myc, which has been suggested to control the expression of p21 Cip1 and ID-1 (Claassen and Hann, 2000; Lasorella et al., 2000) . c-Myc is furthermore known to act as a repressor for TGF-b-induced p15
Ink4b expression (Warner et al., 1999; Staller et al., 2001) , but p15
Ink4b levels were relatively weak and not consistently affected compared to p21 Cip1 , even though a substantial knockdown in Smad3 expression restored c-Myc to almost normal levels (Figure 4b ). Also, p21
Cip1 induction or ID-1 reduction caused by TGF-b were not at all compromised in cells in which Smad4 downregulation restored c-Myc expression (Figures 2c, 4c) . The apparent contradiction for the role of c-Myc in p15 and p21 expression can eventually be resolved by recent observations, indicating that Smads may function as 'cofactors' for c-Myc in multicomponent transcriptional complexes Feng et al., 2002) . According to this model the reduced amounts of Smad3 or Smad4 in our approach interfere with inhibition of the c-myc promoter, but at the same time may be too limited to function as corepressors for c-Myc-mediated p15 suppression. A functional association of Smad3 and Smad4, but not Smad2, with the c-myc promoter in HaCaT cells has been described (Chen et al., 2002) and is corroborated by our data (Figure 4 ). In the case of p21
, simply restoring c-Myc levels is apparently not sufficient to suppress its induction, since Smad4 inhibition has no effect on p21 levels (Figure 4c ). Specifically, Smad3 appears to be responsible for TGF-b-mediated p21
Cip1 induction, which indicates that Smad3 levels may be more decisive for p21
Cip1 expression than c-Mycmediated repression (Figure 4b ).
The identification of signaling events that depend exclusively on Smad3, but not on Smad4 is unexpected, since Smad4 is generally considered to function as the common Co-Smad present in all Smad signaling complexes, and thus to be crucial for TGF-b signaling Smad2, Smad3 and Smad4 in TGF-b signalling A Kretschmer et al (Hill, 1999; Roberts and Derynck, 2001; Attisano and Wrana, 2002; Moustakas and Heldin, 2002) . However, recent studies indicate that exceptions from the current scheme of Smad function and complex formation might exist: R-Smads appear to be able to function with CoSmads other than Smad4 or with no Co-Smads at all (Massague and Wotton, 2000; Weinstein et al., 2000; Moustakas et al., 2001) . Consistent with this observation, mouse fibroblasts with a targeted disruption of Smad4 exhibit a normal response to TGF-b-mediated growth inhibition and still induce the classical TGF-b response genes (Sirard et al., 2000) . Our data furthermore suggest that individual Smad molecules exhibit distinct roles in TGF-b-dependent gene expression in different human cell types such as HaCaT keratinocytes and MCF-10A mammary epithelial cells. It is therefore possible that TGF-b directs the formation of variable Smad complexes for the regulation of a specific gene in different cell types. In agreement with this, knockout studies revealed differential roles for Smad3 in TGF-b-mediated signaling depending on the cellular context (Ashcroft et al., 1999; Datto et al., 1999; Hill, 1999) .
It will be important to understand the contribution of individual Smads to TGF-b signaling with respect to their tumor suppressive role or at later stages during tumorigenesis their growth enhancing capabilities. Elucidating their potential role in diseases with deregulated TGF-b signaling such as cancer, fibrosis, defects in wound healing or immune responses will aid in developing more specific approaches for therapeutic intervention.
Materials and methods
Cell culture
HaCaT human keratinocytes (Boukamp et al., 1988) were obtained from P Boukamp (DKFZ, Heidelberg, Germany) and cultured at 371C in Dulbecco's modified Eagle medium (DMEM) containing 10% FCS. The human breast epithelial MCF-10A cell line (Soule et al., 1990) was obtained from the American Type Culture Collection (ATCC) and grown in a 1 : 1 mixture of Ham's F12 medium and DMEM containing 2.5 mM L-glutamine, 5% horse serum, 10 mg/ml insulin, 5 mg/ml hydrocortisone, 100 ng/ml cholera toxin and 20 ng/ml epidermal growth factor.
Transfections were carried out in 96-well or 10-cm plates (at 30-50% confluency) by using cationic lipids such as Oligofectamine (Life Technologies) or L8 (atugen AG/GOT, Berlin, Germany) according to the manufacturer's instructions. GBs were transfected by adding a preformed 5 Â concentrated complex of GB and lipid in serum-free medium to cells in complete medium. The total transfection volume was 100 ml for cells plated in 96 wells and 10 ml for cells in 10 cm plates. The final lipid concentration was 1.0-2.0 mg/ml depending on cell density; the GB concentration is indicated in each experiment.
TGF-b1 (Roche Applied Science or Calbiochem) was added at 2 ng/ml either directly into growth medium or after 24 h synchronization in serum-free medium as indicated in the respective experiments.
Antibodies
The murine monoclonal anti-p110 antibody U3A has been described (Klippel et al., 1994) . Rabbit polyclonal antiphospho Rb (Ser795) antibody was obtained from Cell Signaling Technology. The murine monoclonal anti-c-Myc antibody (C-33), the polyclonal anti-Smad2/Smad3 antibodies (FL-425), anti-inhibitor of differentiation/inhibitor of ID-1 antibodies (JC-FL) and anti-p15
Ink4b antibodies (C-20) were from Santa Cruz Biotechnology. The mouse monoclonal anti-Smad2 antibody and anti-PAI-1 antibody were from Transduction Laboratories (Becton Dickinson). The rabbit polyclonal HO-1 antibody (sc-10789) and a goat polyclonal anti-Smad3 antibody were obtained from Santa Cruz Biotechnology. The mouse monoclonal anti-Smad4 antibody (SMD46), anti-transglutaminase 2 (TGase 2) antibody (TG100) and anti-p21
Cip1/waf antibody (CP74) were obtained from Neomarkers.
GB antisense oligonucleotides
The (GB) molecules and their corresponding mismatch control oligonucleotides (mm) used have the following sequences:
Sequences are given in 5 0 -3 0 direction. The respective mismatch positions (four per GB molecule) in the mm control oligomers are underlined. Details of the synthesis and structure of GBs representing third-generation antisense oligonucleotides have been described recently by Sternberger et al. (2002) . Briefly, GBs have the following schematic structure: capnnnnnnnNNNNNNNNNnnnnnnn-cap. Hereby, 'cap' represents inverted deoxy abazic end modifications preventing exonuclease attacks; n stands for 2 0 -O-methyl ribonucleotides (A, G, U, C); N represents phosphorothioate-linked deoxyribonucleotides (A, G, T, C). GBC is composed of random 2 0 -O-methyl ribonucleotides and random phosphorothioate linked deoxyribonucleotides. The oligos were synthesized in Trityl-on form and after deprotection initially purified on C-18 cartridges followed by HPLC purification (Fritz et al., 1978) . The purity of the final products was characterized by capillary electrophoresis and the identity was confirmed by MALDI-TOF spectrometry. 
Determination of the relative amounts of RNA levels by Taqman analysis
The RNA of cells transfected in 96-wells was isolated and purified using the Invisorb RNA HTS 96 kit (InVitek GmbH, Berlin). Inhibition of Smad mRNA expression was detected by multiplex real-time RT-PCR (Taqman) analysis using 300 nM Smad forward primer, 300 nM Smad reverse primer and 100 nM of Smad Taqman probe (Fam labelled) in combination with 40 nM b-actin forward primer, 40 nM b-actin reverse primer and 100 nM of the b-actin Taqman probe (Vic labeled).
The reaction was carried out in 50 ml and assayed on the ABI PRISM 7700 Sequence detector (Applied Biosystems) according to the manufacturer's instructions under the following conditions: 481C for 30 min, 951C for 10 min, followed by 40 cycles of 15 s at 951C and 1 min at 601C. The following primers were used:
Preparation of cell extracts and immunoblotting
Cells were washed twice with cold phosphate-buffered saline and lysed at 41C in lysis buffer containing 20 mM Tris (pH 7.5), 137 mM NaCl, 15% (vol/vol) glycerol, 1% (vol/vol) Nonidet P-40 (NP-40), 2 mM phenylmethylsulfonyl fluoride, 10 mg aprotinin/ml, 20 mM leupeptin, 2 mM benzamidine, 1 mM sodium vanadate, 25 mM b-glycerol phosphate, 50 mM NaF and 10 mM Na pyrophosphate. Lysates were cleared by centrifugation at 14 000 g for 5 min and aliquots of the cell extracts containing equal amounts of protein were analysed for protein expression by Western blotting: Samples were separated by SDS-PAGE and transferred to nitrocellulose filters (Schleicher and Schuell). Filters were blocked in TBST buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% (vol/ vol) Tween-20, 0.5% (wt/vol) sodium azide) containing 5% (wt/vol) dried milk. The respective antibodies were added in TBST at appropriate dilutions. Bound antibody was detected using anti-mouse-or anti-rabbit-conjugated horse radish peroxidase (Transduction Laboratories/Becton Dickinson) in TBST, washed, and developed using the SuperSignal West Dura (Pierce) or ECL (Amersham) chemoluminescence substrates.
DNA content analysis by flow cytometry
Cells were harvested by trypsinization and centrifugation for 3 min at 400 g. The cells were fixed and permeabilized in 70% ethanol for 15 min. After a series of washes in PBS, cell clumps and RNA were digested by successive incubation with buffered solutions containing trypsin or RNase (Cycle Test Plus DNA Reagent kit, Beckton Dickinson). After addition of propidium iodide-staining solution DNA content analysis was carried out by fluorescence-activated cell sorting (FACS) using a FACScalibur (Becton Dickinson). Data were evaluated using the ModFit software.
Oligonucleotide array expression analysis RNA sample collection, generation of biotinylated cRNA probe and hybridization to Affymetrix Human Genome U95 Set (HG U95A-E) was carried out essentially as described in the standard Affymetrix (Santa Clara, CA, USA) protocol. Absolute analysis of each chip and comparative analysis of samples were carried out by using the Affymetrix software (Microarray Suite, version 5.0). Filter criteria were applied to samples treated in the absence or presence of TGF-b: Only probe sets with a 'difference call' (decrease or increase) by the GeneChip software were allowed to pass. To account for high noise at low signal intensities, probe sets that were called 'absent' in both, TGF-b treated and untreated samples, were eliminated. Table 1 shows probe sets with more than 2.5-fold differential signal intensities derived from samples with or without TGF-b treatment. 
